Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14764889 | 0.83 | P2RX7 (0.73) | P2RX7MEN1KMT2ACA2 | |
| SCHEMBL3454922 | 0.83 | P2RX7 (1.00) | P2RX7CA2 | |
| SCHEMBL5431054 | 0.80 | P2RX7 (0.60) | P2RX7MEN1KMT2ACA2 | |
| SCHEMBL23902890 | 0.79 | TSHR (1.00) | TSHRUSP2MEN1KMT2ATP53 | |
| SCHEMBL21082070 | 0.79 | CYP17A1 (0.61) | P2RX7TSHRTHRBUSP2MEN1 | |
| SCHEMBL7570202 | 0.76 | P2RX7 (1.00) | P2RX7CA2TP53 | |
| SCHEMBL19354785 | 0.76 | P2RX7 (0.72) | P2RX7MEN1KMT2ACA2 | |
| SCHEMBL17483924 | 0.76 | P2RX7 (0.75) | P2RX7CA2 | |
| SCHEMBL4879622 | 0.74 | P2RX7 (0.73) | P2RX7CA2 | |
| SCHEMBL7667554 | 0.74 | P2RX7 (0.62) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644041-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 ANTAGONIST AND SULFASALAZINE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | claimed |
| WO-2004105797-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 ANTAGONIST AND SULFASALAZINE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| EP-1036059-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2002-09-18 | — | — | EP | claimed |
| US-20010003121-A1 | Novel compounds | ASTRAZENECA UK LIMITED | 2001-06-07 | — | — | US | claimed |
| EP-1036059-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-20010003121-A1 | Novel compounds | ASTRAZENECA UK LIMITED | 2001-06-07 | — | — | US | disclosed |
| US-6201024-B1 | EFFECTIVE P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISORDERS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003121-A1 | Novel compounds | APP, BACE1, CHRNA5 | P2RX7 311/4885TSHR 3980/4885THRB 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.